Inogen (NASDAQ:INGN) Upgraded at StockNews.com

StockNews.com upgraded shares of Inogen (NASDAQ:INGN) from a hold rating to a buy rating in a research note released on Tuesday morning.

Separately, Needham & Company LLC reaffirmed a “hold” rating on shares of Inogen in a research note on Friday, November 8th.

Inogen Price Performance

Shares of INGN traded down $0.13 during mid-day trading on Tuesday, reaching $9.82. The company had a trading volume of 31,840 shares, compared to its average volume of 332,986. The company’s 50-day moving average is $9.88 and its 200-day moving average is $9.49. Inogen has a twelve month low of $4.93 and a twelve month high of $13.33. The company has a market capitalization of $233.91 million, a P/E ratio of -4.42 and a beta of 1.04.

Institutional Investors Weigh In On Inogen

Hedge funds have recently added to or reduced their stakes in the stock. Meeder Asset Management Inc. bought a new position in Inogen in the 2nd quarter worth approximately $30,000. CWM LLC raised its holdings in Inogen by 2,185.9% during the 2nd quarter. CWM LLC now owns 6,629 shares of the medical technology company’s stock worth $54,000 after purchasing an additional 6,339 shares during the last quarter. Susquehanna Fundamental Investments LLC acquired a new position in Inogen during the 1st quarter valued at about $81,000. Pitcairn Co. bought a new position in shares of Inogen in the 1st quarter valued at about $86,000. Finally, Verition Fund Management LLC acquired a new stake in shares of Inogen during the 3rd quarter worth approximately $106,000. Institutional investors own 89.94% of the company’s stock.

Inogen Company Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.